HOME >> BIOLOGY >> NEWS
Other highlights in the Feb. 20 issue of JNCI

Social Factors May Affect Survival in African-American Lung Cancer Patients
A new study suggests that socioeconomic status and other social circumstances could be responsible for decreased physical health at the time of diagnosis among African-American patients with non-small-cell lung cancer, which may explain disparities in survival rates between African-American and non-African-American patients who receive the same treatment for their cancer.

A. William Blackstock, M.D., of the Wake Forest University School of Medicine, Winston-Salem, N.C., and colleagues pooled data from five clinical trials of treatments for non-small-cell lung cancer and found that the one-year survival rate was 22% among African-American patients and 30% among non-African-American patients. The investigators collected information on the patients to determine if the difference was related to innate characteristics of the disease in the two ethnicities or to disparities in health care.

They found that both groups of patients had similar stages of disease when they entered the clinical trials; however, substantially more African-American patients had a worse performance status (the ability to perform physical activity) and had experienced weight loss associated with their disease. (Both of these factors are known to have a negative impact on survival.) After the investigators performed statistical tests to adjust for these factors, there was no difference in outcome between the two ethnic groups.

They also found that African-American patients were more likely to be unmarried, to be uninsured or rely upon Medicaid, and in, general, to have a lower income. The authors note that these factors are associated with decreased overall health, and, by extension, survival outcomes. They conclude that these results lend further support to evidence that equal treatment of racially diverse patients with equivalent pretreatment prognostic features results in equal outcom
'"/>

Contact: Linda Wang
jncinews@oup-usa.org
301-594-2927
Journal of the National Cancer Institute
19-Feb-2002


Page: 1 2 3 4

Related biology news :

1. Other highlights in the September 1 JNCI
2. Other highlights in the August 18 JNCI
3. Other highlights in the August 4 JNCI
4. Other highlights in the July 7 JNCI
5. Other highlights in the June 16 JNCI
6. Other Highlights in the June 2 JNCI
7. Other highlights in the May 19 JNCI
8. Other highlights in the May 5 JNCI
9. Other highlights of the March 17 issue of JNCI
10. Other highlights in the March 3 issue of JNCI
11. Other highlights in the February 18 issue of JNCI

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/5/2020)... ... , ... Regenative Labs has received approval from the Centers for Medicare & ... first Wharton’s jelly allografts to be assigned a Q code and be approved for ... Wharton’s jelly allograft product to be recognized as a 361 HCT/P by CMS regulated ...
(Date:7/18/2020)... ... July 16, 2020 , ... A study has been published ... Neoasis™ active noise control device to attenuate typical noises in a simulated neonatal ... the alarm sounds from patient monitors, ventilators and other bedside devices that would ...
(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. http://www.altrubio.com ... a biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European ... J Martin of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... FARMS, Mich. (PRWEB) , ... August 12, 2020 ... ... Consulting Group, Inc. (EMMA International), a global leader in FDA compliance consulting ... of the nation’s fastest-growing private companies. The list represents a unique look at ...
(Date:8/3/2020)... (PRWEB) , ... August 03, 2020 , ... ... collection, today announced Jim Corrigan, President and CEO has been named one of ... broad cross-section of industry sectors, PharmaVoice 100 honorees are selected based on how ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is ... $3950. With 50 million stem cells total, patients may choose which extremities they would ... for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... transmitter systems that can be configured to drive Klystrons, TWTs, IOTs, and magnetrons. ... drive one or two switches in a push-pull configuration; yielding fast fall time ...
Breaking Biology Technology:
Cached News: